摘要:
A screen to identify a drug for administration to a patient in a regenerative drug therapy that regenerates or repairs a tissue or organ in a human body comprises providing a physiologically relevant human progenitor cell and screening the progenitor cell for a factor that induces differentiation into a cell of the tissue or organ. The physiologically relevant progenitor cell is obtained by:- (a) identifying a target phenotype of interest, being a cell of the tissue or organ that is going to be regenerated; (b) obtaining cells of a first type; (c) determining a differentiation protocol which leads to the appearance of the target phenotype from cells of the first type via a progenitor cell; and (d) modifying the protocol such that the differentiation process is stalled at a stage in which the progenitor cells are present, thereby providing said physiologically relevant progenitor cells for use in the screen.
摘要:
The present invention provides a method of producing a reprogrammed cell, said method comprising exposing Stro-1 + multipotential cells and/or progeny cells thereof to one or more potency-determining factors under conditions sufficient to reprogram the cells. The present invention also provides cells produced by such a method and cells differentiated therefrom in addition to various uses of those cells.
摘要:
Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-&bgr; expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-&bgr; blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-&bgr; blocking agent and treated cells are co-administered to a subject in need thereof.
摘要:
The present invention relates to enzymes which are able to hydrolyse phenylureas, carbamates, and/or organophosphates, as well as polynucleotides encoding these enzymes. The present invention also relates to methods of hydrolysing phenylureas, carbamates, and/or organophosphates.
摘要:
Disclosed is an antibody which can recognize a first antibody. The antibody can specifically recognize either one of the first antibody in an unconjugated form and the first antibody in the form conjugated with an antigen. Specifically, the specifically recognizing antibody is an antibody which can specifically recognize and conjugate with the first antibody in the form conjugated with an antigen (i.e., a domino antibody) or an antibody which can specifically recognize and conjugate with the first antibody in an unconjugated form (i.e., an antibody unlocking antibody).
摘要:
An anti-glypican 3 antibody for use in the treatment of cancer is provided wherein the cancer is selected from the group consisting of lung cancer, colon cancer, mammary cancer, prostate cancer, leukemia, lymphoma and pancreatic cancer.
摘要:
The present invention provides a method of identifying an agent which modulates an activity of a protein, wherein the protein is represented by the amino acid sequence of SEQ ID NO: 1 or has at least 90 % amino acid sequence identity to SEQ ID NO: 1 and transports chloride ions across a cell membrane, comprising: (a) exposing cells which express the protein to the agent; and (b) measuring degree of chloride ion transport in the exposed cells, wherein a change in the degree of chloride ion transport compared to control cells, which express the protein but not exposed to the agent, is indicative of an agent capable of modulating an activity of the protein. The agents identified by this method can be used for the prevention or treatment of various diseases caused by the dysfunction of calcium activated chloride channel.